2026-04-11T08:14:18Z https://pub.unibl.org/oai

oai:pub.unibl.org:40912 2024-06-12T14:24:19Z

FRIO162 Comparable Safety and Immunogenecity and Sustained Efficacy after Transition To SB2 (An Infliximab Biosimilar) vs Ongoing Infliximab Reference Product In Patients with Rheumatoid Arthritis: Results of Phase III Transition Stud /unibl/author/JS Smolen /unibl/author/JY Choe /unibl/author/Nenad Prodanović /unibl/author/I Staykov /unibl/author/E Dokoupilova /unibl/author/A Baranauskaite /unibl/author/R Yatsyshyn /unibl/author/M Mekić /unibl/author/W Porawska /unibl/author/H Ciferska /unibl/author/K Jedrichovicz-Rosiak /unibl/author/A Zelinska /unibl/author/Z Lee /unibl/author/YH Rho 2016 Academic Article text 10 10 /unibl/sci/idNaucniRad:25131 ANNALS OF THE RHEUMATIC DISEASES 0003-4967 https://pub.unibl.org/s/cir/item/40912